Cell free DNA is often regarded as a source of genetic cancer biomarkers, but the related mechanisms of DNA release, composition and biological activity remain unclear. Here we show that rat epithelial cell transformation by the human H-ras oncogene leads to an increase in production of small, exosomal-like extracellular vesicles by viable cancer cells. These EVs contain chromatin-associated double-stranded DNA fragments covering the entire host genome, including full-length H-ras. Oncogenic N-ras and SV40LT sequences were also found in EVs emitted from spontaneous mouse brain tumour cells. Disruption of acidic sphingomyelinase and the p53/Rb pathway did not block emission of EV-related oncogenic DNA. Exposure of nontransformed RAT-1 cells to EVs containing mutant H-ras DNA led to the uptake and retention of this material for an extended (30 days) but transient period of time, and stimulated cell proliferation. Thus, our study suggests that H-ras-mediated transformation stimulates vesicular emission of this histone-bound oncogene, which may interact with non-transformed cells.
Introduction
Several lines of evidence suggest that mutant oncogenes are not confined to their host cancer cells, but may also exit them and interact with distant cells [1] . Indeed, insoluble oncoproteins, such as epidermal growth factor receptor (EGFR/EGFRvIII), KRAS or MET have been found to exit cancer cells as cargo of extracellular vesicles (EVs) [2] [3] [4] , the production of which oncogenes stimulate [2, 5] . Similarly, oncogenic transcripts and non-coding RNA are found in the cargo of EVs released by different cancer cells [6] [7] [8] . Notably, horizontal transfer of oncogenecontaining EVs evokes cellular responses reminiscent of malignant transformation and impacts growth, inflammation and angiogenesis [2] [3] [4] 9, 10] .
The mechanisms of packaging and vesicular emission of proteins and nucleic acids are poorly understood and controversial [11] . Processes of membrane blebbing and protein clustering on the cell surface have been previously implicated [11, 12] , including in the release of larger EVs (100-1,000nm) known as ectosomes, microvesicles or large oncosomes [5] . Alternatively, endocytosis of membrane receptors and their interactions with subcellular vesicle trafficking pathways may result in formation of small EVs (50-100nm) known as exosomes [7, 11, 13] . Other vesiculation pathways may also lead to the emission of oncogenic proteins and RNA, which are thereby protected from degradation and conditioned for intercellular transfer.
Mutant oncogenes may also exit cancer cells as circulating tumour DNA (ctDNA). This property attracted considerable attention as a way to remotely and continually access driver mutations in biofluids of cancer patients [14, 15] . While the nature and biogenesis of ctDNA is presently unclear, its presence is often attributed to necrosis and cellular breakdown leading to the release of free DNA, nucleosomes and chromatin into the surroundings [15] . However, the considerable stability of ctDNA [16] suggests the existence of protective mechanisms that may involve cellular vesiculation. Indeed, oncogenic DNA sequences were found in large vesicular structures known as apoptotic bodies (ABs) formed upon death of cancer cells [17] . EVs emanating from viable cancer cells were also found to contain single and double-stranded DNA [8, [18] [19] [20] [21] .
However, the scope, nature and biological significance of this emission remain poorly characterized.
Here we show that oncogenic H-ras drives vesiculation of intestinal epithelial cells resulting in shedding of small EVs that contain chromatin-associated double-stranded DNA sequences representative of the entire host cell genome. We also document EV-mediated transfer of H-ras DNA to recipient cells and their concomitant proliferative responses. Thus, we postulate that oncogenic mutations can serve to propagate extracellular emission of mutant DNA via EVs that may interact with non-transformed cells.
Materials and methods
Cells and culture conditions. The following cell lines were used: IEC-18 -non-tumourigenic, immortalized rat intestinal epithelial cell line; RAS-3 -tumourigenic variant of IEC-18 cells transfected with the V12 mutant c-H-ras human oncogene; Spontaneous primitive glioblastomalike brain tumour (PBT) cell lines -generated by integrating N-ras and SV40LT expression vectors into neonatal mouse brain using the sleeping beauty transposase, as described [22] . PBTs were generated in either wild type C57BL6 mice or in their strains harbouring null mutation of the acidic sphingomyelinase gene (ASMase-/-), or in heterozygous littermates (ASMase+/-), from which cell lines were established; RAT-1 -immortalized, non-tumourigenic rat fibroblasts.
IEC-18 and RAS-3 cells were grown as previously described [23] . PBT and RAT-1 cells were maintained in DMEM supplemented with 10% FBS and 1% Penn/Strep. For the experiments, FBS added to the media was EV-depleted by ultracentrifugation at 150,000Xg for 5 hours.
Isolation of extracellular vesicles. EVs were obtained by ultracentrifugation as previously described [2, 24] . Briefly, conditioned media was centrifuged at 400Xg for 10 min to remove cell debris, followed by filtration through a 0.2µm PES filter (#565-0020, Thermo Fisher Scientific).
The filtrate was ultracentrifuged at 110,000Xg for 1 hour to isolate EVs. For differential centrifugation, the filtrate was first spun at 10,000Xg for 30 min (to separate P2/P3 fraction) and then at 110,000Xg for 1 hour to isolate P4 fraction. Council of Animal Care. Numerical data were processed for significance using two-tailed t-test with the threshold p-value of 0.05.
Transmission Electron Microscopy (TEM)
.
Results
Oncogenic H-ras stimulates formation of extracellular vesicles. We have previously observed that expression of the oncogenic EGFRvIII drives vesiculation of cancer cells [2] . To examine whether intracellular oncogenes also exhibit a similar property, we employed the wellcharacterized model of rat intestinal epithelial cells (IEC-18) and their human H-ras transformed RAS-3 variant. Interestingly, electron microscopy (TEM) of conditioned media collected from the respective cell lines revealed the presence of exosomal-like EVs, approximately 100nm in diameter and in vastly larger numbers for RAS-3 cells versus IEC-18 (Fig. 1A) . Membranes of both cell types were also labelled with the FM1-43 dye resulting in fluorescence of their derived EVs. This emission was quantified using a fluorescence reader (Victor), once again indicating more pronounced vesiculation of RAS-3 cells (Fig. 1B) . As FM1-43 measures all membranes emanating from cultured cells, we also performed a nanoparticle tracking analysis (NTA) to gain insight into the size distribution of EVs produced by IEC-18 and RAS-3 cells. We observed that RAS-3 cells emitted elevated numbers of EVs in the size intervals between 51-250nm, which was consistent with TEM results (Fig. 1C) . These observations suggest that transformation by mutant H-ras stimulates production of exosomal-like EVs.
Extracellular vesicles contain double-stranded genomic DNA sequences including oncogenic Hras. While oncogenic mutations lead to EV-mediated emission of corresponding oncoproteins and transcripts [2, 6, 9] , it is unclear whether this is also true for DNA. To address this question, we isolated DNA from RAS-3 cells as well as their EVs and performed PCR amplification of the human H-ras gene, which was found to be present in both entities ( Fig. 2A) . H-ras DNA was located in the EV lumen, as DNase treatment of intact EVs (in PBS) did not eliminate the signal, while disruption of EVs in the DNase buffer resulted in the disappearance of the band (Fig. 2B) .
One mechanism whereby genomic DNA may be encapsulated within the cargo of EVs is the case of apoptosis where dying cells break up into large ABs (>1,000nm), containing nuclear DNA fragments [25] . However, this was not the case for cultured RAS-3 cells, which were highly viable (>95% trypan blue exclusion) and the EVs they emitted were of small, nearexosomal sizes (Fig. 1) . Therefore, we reasoned that H-ras sequences in this material may represent the previously reported single-stranded [8] , or double-stranded [18] [19] [20] [21] vesicular DNA.
To discriminate between these possibilities, DNA isolates from RAS-3 EVs were treated with the restriction enzyme RsaI (specific for double-stranded DNA), which indeed resulted in a significant leftward shift in the Bioanalyzer QC profile. EV-associated DNA was therefore found to be largely double-stranded (Fig. 2C) . This is consistent with our observation that Exonuclease-I, which only cleaves single-stranded DNA, had no effect on the amount of total DNA present in RAS-3 EVs (data not shown) or detection of H-ras sequences by PCR amplification (Fig. 2D) .
Collectively, these results suggest that H-ras-triggered vesiculation leads to the emission of double-stranded genomic DNA including H-ras sequences.
Subsets of extracellular vesicles preferentially carry chromatin and mutant H-ras sequences.
Among multiple subsets of EVs [11] , those emanating from the plasma membrane are often larger, sedimented at lower centrifugal forces (P2/P3) and dependent on ASMase activity [24] . In contrast, smaller exosomal-like EVs are formed within endosomes, sediment at higher centrifugal forces (P4) and may be regulated by p53 [26] . To further investigate the role of these variables in the emission of EV-related DNA, we isolated P2/P3 and P4 fractions of RAS-3 media and assessed for the human H-ras DNA content by PCR. Interestingly, H-ras DNA was preferentially (though not exclusively) concentrated in the P4 fraction (Fig. 2E) . We also used ELISA that quantifies DNA/histone complexes to test whether, and which, EVs may contain chromatin. Once again, the DNA/histone signal was concentrated in P4 and not in the P2/P3 fractions (Fig. 2F) . These results suggest that extracellular DNA, including H-ras nucleosomes, exit cells via small, exosomal-like EVs (Fig. 1) .
DNA-containing extracellular vesicles are generated independently of ASMase.
To explore the mechanisms of vesicular DNA emission, we generated primitive brain tumour (PBT) cell lines harbouring N-ras and SV40LT oncogenes in the wild type or ASMase-deficient background [22] . These cells are deficient for both Rb/TP53 activity (due to SV40LT expression [27] ) and ASMase (due to targeted insertion of neomycin expressing cassette into the gene [28] ), the changes affecting both known vesiculation pathways of exosomal and ectosomal biogenesis, respectively [24, 26] . Analysis of this unique panel of cell lines revealed the emission of EVs containing oncogenic N-ras and SV40LT sequences, suggesting EV biogenesis may be independent of the two pathways (Fig. 2G) .
DNA contained in extracellular vesicles represents the entire genome.
To better understand the nature of DNA present in RAS-3 vesicles, EV DNA sequences were obtained by whole genome sequencing (WGS). The presence of human H-ras oncogene in EVs was validated by blasting the human sequence onto two scaffolds, which were generated by assembling unmapped reads that do not correspond to the rat genome ( Fig. 3A; Orphan; Green). PCR amplification also indicated that large fragments (777bp; 2200bp) were present in EVs including the full-length Hras oncogene (3308bp; Fig. 3B ), which is consistent with Bioanalyzer QC data (700-10000bp; Fig. 2C ). Moreover, we investigated the copy number variation (CNV) of RAS-3 EV-associated DNA. While the CNV plot suggests some increase in contribution of certain loci (chromosome 11 -upward shift), we have not detected any genomic regions that would be selectively included in EVs (Fig. 3C) , as suggested earlier by us [18] and others [20] . Indeed, over 90% of the cellular genome was found in EVs with at least 3 times the coverage of sequences (Fig. 3D) .
Collectively, these results suggest that EV-associated DNA represents the entire genome of donor cells and contains full-length H-ras oncogene.
Extracellular vesicle -mediated intercellular transfer of oncogenic H-ras DNA. Intercellular
transfer of oncogenic DNA has thus far been attributed to the uptake of ABs [17, 25] and cell-free DNA (cfDNA) [29] . We wished to determine whether DNA-containing EVs emitted by viable RAS-3 cells could also mediate the transfer of oncogenic H-ras. Thus, RAS-3 cells were surface labelled with PKH26, which binds and fluorescently tags plasma membrane and EVs. We observed that addition of such EVs to cultures of RAT-1 cells leads to fluorescent labelling of the latter cells (Fig. 4A) , a finding indicative of an avid uptake of EVs by these cells. To assess whether this interaction led to a transfer of H-ras DNA, recipient RAT-1 cells were lysed at different time points and assayed by PCR for the presence of human-specific (RAS-3-derived)
H-ras signals. Remarkably, such signal was readily detected within 2 days of EV exposure, and was still present as long as 30 days later, albeit at diminished levels (Fig. 4B) . We have not observed a time-dependent enrichment or permanent presence of H-ras DNA in the recipient cells, which suggests that the effects of this transfer do not amount to permanent transformation in spite of the fact that RAT-1 cells can readily be transformed using H-ras expression vectors (data not shown). However, we noticed morphological changes in RAT-1 cells immediately after their exposure to RAS-3-derived EVs. To interrogate more closely the underlying biological effects, RAT-1 cells were treated with RAS-3-derived EVs and tested for time-dependent proliferative response using the MTS assay. We observed a higher proliferation rate of these cells 5 days post-treatment (Fig. 4C) . Overall, these results suggest that formation of EVs serves to emit genomic DNA from ostensibly viable cancer cells. This material includes full-length Hras oncogene sequences which can be transferred to non-tumourigenic cells and remain there for extended periods of time, while these cells exhibit increased proliferation.
Discussion
Our present study extends prior findings suggesting the extracellular emission of oncogenes [2, 6, 17, 25] . In particular, we provide evidence that oncogenic H-ras drives emission of small EVs containing H-ras DNA, which may enter and remain within recipient, non-transformed cells for extended periods of time, with concomitant mitogenic response. While the nature of this proliferative effect is presently unclear, it is unlikely a sign of permanent transformation due to the decline of EV-related H-ras DNA in recipient cells. While the entry of exogenous DNA into stromal cells was reported to trigger DNA repair [30] , we did not detect such responses in RAT-1 assays (data not shown), suggesting a role of cellular background.
We also observed that EVs emitted from viable cancer cells contain DNA covering the entire (rat) genome, including the exogenously introduced human H-ras oncogene. Moreover, these EV-associated DNA are long fragments, double-stranded and contains histones, thereby suggesting their derivation from cellular chromatin. This differs from the results of Balaj et al.
who reported the presence of single-stranded DNA in tumour-derived EVs [8] . The disparity could be related to a different cellular source, or to the diversity of vesiculation processes involved in various systems. However, the ability of cancer cells to emit double-stranded DNA is consistent with several recent observations [18] [19] [20] [21] .
It is unclear how DNA becomes incorporated into exosomal-like EVs. While EVs we describe possess some features of exosomes, their biogenesis and nomenclature are complex and controversial [11] . Thus far, we ruled out the involvement of TP53 and ASMase in vesicular emission of oncogenic DNA [24, 26] , but additional mechanisms are being investigated.
Our study also offers several general implications. First, we suggest that certain types of oncogenic transformation events may result in the increased emission of EVs containing mutant DNA to biofluids, and this may represent a significant proportion of cfDNA [20] . Second, EVs could be a source of extracellular histones, nucleosomes and chromatin, and may trigger both localized and systemic biological effects [31] by affecting cellular viability and proliferation.
Third, while we detect double-stranded DNA in EVs that possess exosomal-like characteristics and may be present in standard exosomal preparations, formation of DNA-containing EVs likely represents a distinct process [11] . Thus, further studies are warranted to elucidate the biogenesis, activity and clinical utility of DNA-containing EVs in cancer. 
